Search Results - "Nash, Tamsin"

Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic by Zanuso, Valentina, Nash, Tamsin, Casolino, Raffaella, Armstrong, Gregory, Pallise, Ona, Milne, Jen, Braconi, Chiara

“…With the increasing of novel therapeutics for the treatment of Biliary Tract Cancers (BTC), and the need to assess their socio-economic impacts for national…”
Get full text

Recommended antimicrobial therapy for common inpatient infections: a comparative review of guidelines across 51 hospital trusts in England by Pan, Daniel, Hills, George, Hamilton, Ashley Ryan, Nash, Tamsin, Hine, Thomas, Whitehorn, Sarah, Barlow, Gavin

“…BackgroundThe number of different antimicrobial recommendations between hospital trusts for the same indication in England is unknown.AimWe aimed to evaluate…”
Get full text

Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer by Battisti, Nicolò Matteo Luca, Andres, Maria Sol, Lee, Karla A., Ramalingam, Sivatharshini, Nash, Tamsin, Mappouridou, Stephanie, Senthivel, Nishanthi, Asavisanu, Kalaprapa, Obeid, Mariam, Tripodaki, Elli-Sophia, Angelis, Vasileios, Fleming, Emily, Goode, Emily F., John, Susan, Rosen, Stuart D., Allen, Mark, Stanway, Susannah, Lyon, Alexander R., Ring, Alistair

“…Purpose Trastuzumab improves survival in patients with HER2+ early breast cancer. However, cardiotoxicity remains a concern, particularly in the curative…”
Get full text

Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers by Casolino, Raffaella, Amato, Francesco, Rae, Colin, Puttagunta, Srikanth, Braconi, Chiara, Nash, Tamsin, MacLeod, Martin, Sanchon-Sanchez, Paula, Roxburgh, Patricia, Evans, Jeff, Graham, Janet, Duthie, Fraser, Valeri, Nicola, Herzyk, Pawel, Galbraith, Julie

Get full text

Abstract P1-17-08: Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience by Battisti, Nicolò Matteo Luca, Morrison, Laura, Nash, Tamsin, Senthivel, Nishanti, Kestenbaum, Samantha, Begum, Parvin, Obeid, Mariam, Hayhurst, William, Yang, Dorothy, Gafoor, Shafiah, Brown, Caroline, Rehman, Farah, Kenny, Laura, Hatcher, Olivia, Susan, Susan, Williams, Jennet, Brown, Anna, Rozati, Hamoun, Alexandros, Alexandros, Sawyer, Elinor, Gousis, Charalampos, Karapanagiotou, Eleni, Rigg, Anna, Rapti, Kleopatra, Roylance, Rebecca, Beresford, Mark, Gee, Abigail L, Konstantis, Apostolos, King, Judy, Nathan, Mark, Spurrell, Emma, Pearce, Mark, Bradwell, Dane, Denton, Arshi, Swain, Kate, McGrath, Sophie, Allen, Mark, Ring, Alistair, Johnston, Stephen, Raja, Fharat

“…Abstract Background Abemaciclib is approved in 1st and 2nd line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). However,…”
Get full text